Quintrio
Home

SERVICES-MEDICAL LABORATORIES

RadNet, Inc. Common Stock

RDNT

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.

Last trade $76.04
Day change -$0.85 (-1.11%)
Day range $74.15 – $77.00
Volume 127,371
Market cap $6.06B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.06B
Price / earnings
—
Price / book
5.4×
Price / sales
2.54×
EV / sales
2.78×
EV / EBITDA
23.74×

Profitability

Earnings per share
-$0.28
Return on assets
-0.52%
Return on equity
-2%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.19×
Current ratio
1.49×
Quick ratio
1.49×
Cash ratio
1.05×

Cash flow

Price / cash flow
17.41×
Price / free cash flow
—
Free cash flow
-$267.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RDNT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$638.26M$622.72M$575.63M$547.71M$522.87M$498.23M$471.4M$477.1M
Cost of revenue$552.38M$0$0$471.78M$450.38M$0$0$411.44M
Gross profit$85.88M$622.72M$575.63M$75.93M$72.49M$498.23M$471.4M$65.67M
Selling, general and administrative$0$0$0$0$0$0$0$0
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$50.26M$582.14M$596.94M$41.62M$44.06M$465.63M$489.71M$39.6M
Operating income$35.62M$40.59M-$21.31M$34.32M$28.43M$32.6M-$18.31M$26.07M
Interest expense-$20.68M-$18.15M-$17.66M-$18.13M-$17.36M-$17.19M-$17.24M-$18.07M
Income before taxes$27.51M$26.62M-$32.83M$20.92M$20.27M$23.85M-$33.14M$15.32M
Income taxes$8.36M$6.36M-$8.1M$11.06M$6.39M$820K-$3.4M$1.1M
Net income$19.15M$20.25M-$24.73M$9.86M$13.89M$23.03M-$29.74M$14.23M
Net income attributable to common shareholders$4.15M$7.53M-$33.47M-$597K$5.42M$14.45M-$37.93M$5.35M
EBITDA$82.63M$88.08M$25.12M$83.73M$68.23M$69.15M$17.92M$64.56M
Basic earnings per share$0.05$0.10-$0.43-$0.01$0.07$0.19-$0.51$0.07
Diluted earnings per share$0.05$0.10-$0.43-$0.01$0.07$0.19-$0.51$0.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Why RadNet (RDNT) is a Top Momentum Stock for the Long-Term

RadNet (RDNT), a leading national provider of freestanding outpatient diagnostic imaging services, has been highlighted as a stock to watch with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The stock has gained 8% over the past four weeks, with three analysts revising earnings estimates upward in the last 60 days, increasing the Zacks Consensus Estimate to $0.56 per share for fiscal 2026.

Zacks Investment Research

Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Surpass Estimates

Elanco Animal Health reported Q3 2026 earnings of $0.27 per share, beating consensus estimates of $0.20, with a 35% earnings surprise. Revenues reached $1.27 billion, surpassing estimates by 4.91% compared to $1.14 billion year-ago. The company has beaten consensus estimates four consecutive quarters. However, the stock has underperformed the S&P 500 year-to-date, gaining 4.6% versus the market's 7.4%. Zacks assigned the stock a Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

RadNet (RDNT) Soars 9.7%: Is Further Upside Left in the Stock?

RadNet (RDNT) surged 9.7% to $80.26 on investor optimism ahead of its third-quarter 2026 earnings release on November 9. The medical diagnostic imaging operator is expected to report $0.21 EPS and $637.56M in revenue, up 21.9% year-over-year. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that the stock may struggle to sustain momentum without further positive estimate revisions. RadNet carries a Zacks Rank #3 (Hold).

Zacks Investment Research

RadNet (RDNT) Reports Next Week: Wall Street Expects Earnings Growth

RadNet (RDNT) is expected to report Q3 2026 earnings of $0.21 per share with 21.9% revenue growth, but analysts have recently become bearish with an Earnings ESP of -18.07%, making an earnings beat unlikely despite the company's strong historical surprise record of +38.10% in the last quarter.

GlobeNewswire Inc.

RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call

RadNet, Inc. (NASDAQ: RDNT), a national leader in diagnostic imaging services, announced it will host a conference call on November 9, 2026 to discuss its third quarter 2026 financial results. The company operates a network of outpatient imaging centers across 11 states and provides radiology IT and AI solutions through its DeepHealth brand.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.